Scribd
Upload
54 views7 pages

Operating Revenues-The Total Income From Operations Grew by

Zydus Wellness completed the Rs 4,600-crore acquisition of Heinz India's consumer wellness business in January 2019, which included popular brands like Complan, Glucon-D, Nycil and Sampriti Ghee. To fund the acquisition, the company raised Rs 2,575 crore through a preferential share issue and Rs 1,500 crore through non-convertible debentures, with the balance paid through cash reserves. The acquisition provided Zydus Wellness with two large manufacturing facilities, a network of 800 distributors and 20,000 wholesalers, and research, sales, marketing and

Uploaded by

shinjan bhattacharya
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as XLSX, PDF, TXT or read online on Scribd
54 views7 pages

Operating Revenues-The Total Income From Operations Grew by

Zydus Wellness completed the Rs 4,600-crore acquisition of Heinz India's consumer wellness business in January 2019, which included popular brands like Complan, Glucon-D, Nycil and Sampriti Ghee. To fund the acquisition, the company raised Rs 2,575 crore through a preferential share issue and Rs 1,500 crore through non-convertible debentures, with the balance paid through cash reserves. The acquisition provided Zydus Wellness with two large manufacturing facilities, a network of 800 distributors and 20,000 wholesalers, and research, sales, marketing and

Uploaded by

shinjan bhattacharya
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as XLSX, PDF, TXT or read online on Scribd
You are on page 1/ 7

2017-2018

to accelerate the pace of growth, innovate


and create value, and deliver it in a consistent and sustained
way to our stakeholders.

this has been our journey of 23 years - from a turnover of `200 crore
to `11,600 crore,

Shifting market
dynamics have been demanding more differentiation and
greater efficiency, at competitive costs.

Posted sales of `33,324 million, up 3%


on a like-to-like basis; adjusting for GST
impact, the growth was 6%
Launched 64 new products including line
extensions

Operating Revenues- The total income from operations grew by


25% to `119,364 million
from `95,724 million, last year.
Profit-The EBIDTA (Earnings before Interest, Depreciation, Taxation
and Amortisation) grew by 50% to `28,475 million from `19,045
million, last year. The EBIDTA margin as % to total income from
operations improved by 400 basis points to 23.9% from 19.9% last
year. Net profit grew by 19% to `17,758 million from `14,877 million
last year. The net profit margin as % to total income from operations
stood at 14.9% during the year.
2017-2018

Capital Expenditure: The net capital expenditure including


capital work in progress during the year was `9,824 million
The capex during the year was incurred mainly for creation
of new facilities and upgradation and capacity expansion of
existing facilities.

Debt: on March 31, 2018 stood at `38,170 million, as


against `36,146 million last year. Net debt-equity ratio was
0.44:1 as on March 31, 2018, against 0.52:1 as on March
31, 2017.
Question 3 and
4---->>>
Acquisition- it borrowed more to help finance the Rs 4,600-crore acquisition earlier this year of Heinz India’s consumer wellne
business.

1. In January 2019, Zydus Wellness completed the Rs 4,600-crore acquisition of Heinz India's consumer wellness business, whi
included the Complan, Glucon-D, Nycil and Sampriti Ghee brands. The acquisition included two large manufacturing facilities (
Aligarh and another one in Sitarganj) along with operations, research, sales, marketing and support teams, and a network of m
800 distributors and 20,000 wholesalers in 29 states.

2. The funding of the acquisition was through a mix of debt and equity. The company raised Rs 2,575 crore by issuing 18.6 mill
on a preferential basis to Cadila Healthcare (Rs 1,175 crore), Zydus Family Trust (Rs 300 crore), True North (Rs 1,000 crore) and
Investment Fund (Rs 100 crore) at an issue price of Rs 1,382 per share, resulting in an equity dilution of nearly 48%.

The company also raised Rs 1,500 crore by issuing 9.14% secured, redeemable NCDs on a private on a private placement basis
balance payment was made through Rs 550 crore cash available with the company.
Launched 53 new products and posted sales of Rs35338 million upto 6%
Core Strategy- The Company invests approximately 7 to 8% of its annual revenues on innovation.

Operating revenue- the India formulations business, the second largest contributor
to the consolidated revenues, registered sales of Rs. 35,338 million, during the year,
with a growth of 6%.

You might also like